Ergoteles’s Krystal Biotech KRYS Stock Holding History

Ergoteles’s Portfolio KRYS Stock Details KRYS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-15,781	Closed	-$1.26M	–	1278
2023 Q1	$1.26M	Buy	15,781 +1,673	+12%	+$131K	0.05%	413
2022 Q4	$1.12M	Buy	+14,108	New	+$1.05M	0.04%	429
2022 Q1	–	Sell	-17,002	Closed	-$1.19M	–	1440
2021 Q4	$1.19M	Buy	+17,002	New	+$990K	0.05%	372

Other funds holding KRYS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Ergoteles's KRYS Position: Q2 2023 in Review

Ergoteles sold out of Krystal Biotech (KRYS) in Q2 2023, closing a stake of 15,781 shares — an estimated $1.26M sold.

Ergoteles first reported a position in KRYS in Q4 2021 and held it in 3 quarters. The position peaked at $1.26M in Q1 2023. 183 funds tracked by Wall St. Rank hold KRYS as of Q2 2023.

Ergoteles reported no remaining Krystal Biotech position as of Q2 2023 after selling out during the quarter.
Ergoteles sold 15,781 Krystal Biotech shares in Q2 2023, an estimated $1.26M.
Ergoteles first reported a position in Krystal Biotech in Q4 2021 and held it in 3 quarters.
Ergoteles's Krystal Biotech position peaked at $1.26M in Q1 2023.
183 funds tracked by Wall St. Rank held Krystal Biotech as of Q2 2023.

Based on Ergoteles's 13F filing for Q2 2023, filed 14 Aug 2023.